FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170867701> ?p ?o ?g. }

• W3170867701 abstract "Background: Capecitabine is a prodrug of 5-fluorouracil (5-FU) and is converted to 5-FU in tumor tissue. Its primary mechanism of action is the suppression of DNA synthesis via inhibition of thymidylate synthetase. It is mostly used for neoadjuvant chemoradiation, adjuvant chemotherapy for colorectal cancer, metastatic breast, and localized and metastatic gastric cancer, among others. Adverse effects of capecitabine include diarrhea, hand-foot syndrome (HFS), pancytopenia, stomatitis, increased bilirubin, nausea, vomiting, and very rarely adermatoglyphia. Dermatoglyphics refers to fingerprints. Adermatoglyphia refers to the loss of fingerprints. Case review summary: We report the case of a 62-year-old male patient known case of locally advanced colorectal cancer. He presented in the clinic with residual disease after initially being treated with local surgery and chemoradiation with 5-FU. Positron emission tomography (PET) scan done at the time of presentation showed locally advanced disease. He was managed with surgery followed by chemotherapy with oxaliplatin 130 mg/m2 and capecitabine (Xeloda) 1500 mg twice a day for two weeks via three weekly cycles. Post cycle five, the patient complained of grade I HFS symptoms and inability to open a bank account due to loss of fingerprints. The patient was oblivious about this condition before that. After completing his adjuvant treatment that is six cycles of oxaliplatin and Xeloda, his symptoms of the HFS and loss of fingerprints, improved. Conclusion: As this case describes, adermatoglypia is a rare but noticeably side effect of capecitabine with a high chance of reversibility. Similar case reports have been reported with some normalization of fingerprints, after stopping treatment. Fingerprints have been used for centuries as means of identification in banks, aviation, immigration, computers, and mobile phones, amongst others. Awareness regarding the loss of fingerprints due to capecitabine is important for the patient and clinician, and alternative means of identification or other adaptive methods of recognition should be used for these patients." @default.
• W3170867701 created "2021-06-22" @default.
• W3170867701 creator A5036329636 @default.
• W3170867701 creator A5044661839 @default.
• W3170867701 creator A5051572591 @default.
• W3170867701 creator A5065795041 @default.
• W3170867701 date "2021-06-08" @default.
• W3170867701 modified "2023-10-16" @default.
• W3170867701 title "Capecitabine-Associated Loss of Fingerprints: A Case Report of a 62-Year-Old Man With Colorectal Cancer Suffering From Capecitabine-Induced Adermatoglyphia" @default.
• W3170867701 cites W1979186680 @default.
• W3170867701 cites W2000472495 @default.
• W3170867701 cites W2068227862 @default.
• W3170867701 cites W2078701235 @default.
• W3170867701 cites W2087675944 @default.
• W3170867701 cites W2111934463 @default.
• W3170867701 cites W2142827726 @default.
• W3170867701 cites W2568750795 @default.
• W3170867701 cites W2911971971 @default.
• W3170867701 cites W4236662381 @default.
• W3170867701 doi "https://doi.org/10.7759/cureus.15519" @default.
• W3170867701 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8265279" @default.
• W3170867701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34268045" @default.
• W3170867701 hasPublicationYear "2021" @default.
• W3170867701 type Work @default.
• W3170867701 sameAs 3170867701 @default.
• W3170867701 citedByCount "0" @default.
• W3170867701 crossrefType "journal-article" @default.
• W3170867701 hasAuthorship W3170867701A5036329636 @default.
• W3170867701 hasAuthorship W3170867701A5044661839 @default.
• W3170867701 hasAuthorship W3170867701A5051572591 @default.
• W3170867701 hasAuthorship W3170867701A5065795041 @default.
• W3170867701 hasBestOaLocation W31708677011 @default.
• W3170867701 hasConcept C121608353 @default.
• W3170867701 hasConcept C126322002 @default.
• W3170867701 hasConcept C143998085 @default.
• W3170867701 hasConcept C197934379 @default.
• W3170867701 hasConcept C2776694085 @default.
• W3170867701 hasConcept C2777909004 @default.
• W3170867701 hasConcept C2780580376 @default.
• W3170867701 hasConcept C2780962732 @default.
• W3170867701 hasConcept C526805850 @default.
• W3170867701 hasConcept C71924100 @default.
• W3170867701 hasConceptScore W3170867701C121608353 @default.
• W3170867701 hasConceptScore W3170867701C126322002 @default.
• W3170867701 hasConceptScore W3170867701C143998085 @default.
• W3170867701 hasConceptScore W3170867701C197934379 @default.
• W3170867701 hasConceptScore W3170867701C2776694085 @default.
• W3170867701 hasConceptScore W3170867701C2777909004 @default.
• W3170867701 hasConceptScore W3170867701C2780580376 @default.
• W3170867701 hasConceptScore W3170867701C2780962732 @default.
• W3170867701 hasConceptScore W3170867701C526805850 @default.
• W3170867701 hasConceptScore W3170867701C71924100 @default.
• W3170867701 hasLocation W31708677011 @default.
• W3170867701 hasLocation W31708677012 @default.
• W3170867701 hasLocation W31708677013 @default.
• W3170867701 hasOpenAccess W3170867701 @default.
• W3170867701 hasPrimaryLocation W31708677011 @default.
• W3170867701 hasRelatedWork W1974190027 @default.
• W3170867701 hasRelatedWork W1988418397 @default.
• W3170867701 hasRelatedWork W1997133872 @default.
• W3170867701 hasRelatedWork W2029040122 @default.
• W3170867701 hasRelatedWork W2075077394 @default.
• W3170867701 hasRelatedWork W2081174487 @default.
• W3170867701 hasRelatedWork W2145753255 @default.
• W3170867701 hasRelatedWork W2160763249 @default.
• W3170867701 hasRelatedWork W2372468489 @default.
• W3170867701 hasRelatedWork W2465617904 @default.
• W3170867701 isParatext "false" @default.
• W3170867701 isRetracted "false" @default.
• W3170867701 magId "3170867701" @default.
• W3170867701 workType "article" @default.